NCT00090896已完成1 期
A Phase I, Open Label, Study To Evaluate The Safety And Immune Function Effects Of CP-675,206 In Combination With MART-1 Peptide-Pulsed Dendritic Cells In Patients With Advanced Melanoma
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
研究概览
简要总结
RATIONALE: Biological therapies, such as CP-675,206, work in different ways to stimulate the immune system and stop tumor cells from growing. Vaccines may make the body build an immune response to kill tumor cells. Combining CP-675,206 with vaccine therapy may cause a stronger immune response and kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of CP-675,206 when given with vaccine therapy in treating patients with stage III or stage IV melanoma that cannot be removed with surgery.
详细描述
OBJECTIVES:
Primary
- Determine the safety and maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (CTLA4-blocking monoclonal antibody; CP-675,206) administered with autologous dendritic cells pulsed with MART-1 antigen in patients with unresectable stage III or stage IV melanoma.
- Determine the biological activity and immune effects of this regimen in these patients.
Secondary
- Correlate CTLA4 genotype with safety of this regimen and/or immune response in these patients.
- Determine, preliminarily, the efficacy of this regimen, in terms of clinical benefit rate, in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed cutaneous or mucosal melanoma, meeting criteria for 1 of the following:
- •Unresectable stage III disease (locally relapsed unresectable, in-transit lesions, or unresectable draining nodes)
- •Stage IV disease, metastatic to 1 of the following sites:
- •Skin, subcutaneous tissues, or distant lymph nodes
- •Other visceral sites with lactic dehydrogenase ≤ 2 times upper limit of normal (unless due to liver stasis)
- •De novo metastatic disease allowed provided patient refused any standard or approved stage-appropriate therapy for melanoma
- •Measurable disease
- •HLA-A2.1 positive (HLA-A*0201 by molecular subtyping)
- •MART-1-expressing tumor by reverse transcription polymerase chain reaction or immunohistochemistry
- •No symptomatic brain metastases and/or progression of CNS metastases within the past 4 weeks
- •Age 18 and over
- •Performance status ECOG 0-1 OR
- •Karnofsky 70-100%
- •HIV negative
- •Negative pregnancy test
- •Fertile patients must use effective barrier contraception during and for 3 months after study participation
- •More than 30 days since prior immunotherapy for metastatic, relapsed, or primary melanoma
- •More than 30 days since prior chemotherapy for metastatic, relapsed, or primary melanoma
- •More than 4 weeks since prior corticosteroids
- •More than 30 days since prior radiotherapy for metastatic, relapsed, or primary melanoma
- •More than 30 days since prior surgery for metastatic, relapsed, or primary melanoma.
- •More than 30 days since other prior therapy for metastatic, relapsed, or primary melanoma
- •More than 14 days since prior anti-infective therapy
- •More than 4 weeks since prior immune suppressive therapy (e.g., cyclosporine)
排除标准
- •chronic hepatitis B or C
- •inflammatory bowel disease
- •celiac disease
- •history of chronic colitis or other chronic gastrointestinal conditions associated with diarrhea or bleeding
- •active chronic inflammatory or autoimmune disease, including any of the following:
- •Psoriasis
- •Rheumatoid arthritis
- •Multiple sclerosis
- •Hashimoto's thyroiditis
- •Addison's disease
- •Graves' disease
- •Systemic lupus erythematosus
- •active infection OR fever over 100° F within the past 3 days
- •allergy to study drugs
- •symptomatic seizures
- •other medical problem that would preclude study participation
- •prior melanoma immunotherapy containing MART-1 antigen
- •prior anti-T-cell therapy
- •prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (CP-675,206)
- •organ allografts requiring long-term immune suppressive therapy
研究组 & 干预措施
CTLA4-Blocking Monoclonal Antibody
Experimental
干预措施: maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (Biological)
结局指标
主要结局
Maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
时间窗: 3 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAPMalariaNCT01364883University of Oxford39
已完成
1 期
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary HistologyRenal Cell Carcinoma With Clear Cell HistologyCarcinoma, Renal CellRenal Cell Carcinoma of Papillary HistologyRenal Cell Carcinoma With Non-Clear Cell HistologyNCT01672775Agensys, Inc.34
已完成
1 期
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric CancerCLDN18.2-positive Gastric AdenocarcinomaCLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionCLDN18.2-positive Adenocarcinoma of EsophagusNCT01671774Astellas Pharma Global Development, Inc.29
已完成
1 期
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B VaccineVaccine-Preventable DiseasesHepatitis BNCT06147895CHA Vaccine Institute Co., Ltd.30
已完成
1 期
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular DegenerationAge-Related Macular DegenerationNCT02555306Santen Inc.12